Although the addition of biomarkers such as serum prostate-specific antigen levels to prostate cancer diagnosis has increased diagnosis at relatively early stages (Gleason < 7), the current diagnostic algorithm still presents several limitations. This evidence concerns the gene KLK3 and prostate carcinoma.